PMID- 33627439
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20210304
IS  - 2056-5933 (Electronic)
IS  - 2056-5933 (Linking)
VI  - 7
IP  - 1
DP  - 2021 Feb
TI  - Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: 
      considerations before widespread availability of the vaccines.
LID - 10.1136/rmdopen-2020-001553 [doi]
LID - e001553
AB  - Vaccination against SARS-CoV-2 has become available and will hopefully end the 
      current pandemic. Understandably, patients with inflammatory rheumatic diseases 
      (iRMDs) and their physicians are feverishly preoccupied with questions about 
      vaccination and the vaccines against SARS-CoV-2. However, as it will take months 
      before all patients with iRMDs will have access to the vaccines, measures that 
      are taken now in order to increase potential safety and efficacy of the vaccines 
      may impose a risk for the patients with regard to reactivation of their 
      underlying iRMD. The ad hoc commission 'Covid-19' and the board of directors of 
      the German Society for Rheumatology have addressed this topic and have developed 
      considerations, which are intended to answer urgent questions, to take away 
      concerns and fears and to make initial recommendations for patients with iRMDs.
CI  - (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Schulze-Koops, Hendrik
AU  - Schulze-Koops H
AUID- ORCID: 0000-0002-1681-491X
AD  - Division of Rheumatology and Clinical Immunology, Department of Medicine IV, 
      Ludwig Maximilians University of Munich, Munich, Germany 
      hendrik.schulze-koops@med.uni-muenchen.de.
FAU - Specker, Christof
AU  - Specker C
AUID- ORCID: 0000-0003-2504-3229
AD  - Klinik fur Rheumatologie und Klinische Immunologie, KEM Kliniken Essen-Mitte, 
      Essen, Germany.
FAU - Skapenko, Alla
AU  - Skapenko A
AD  - Division of Rheumatology and Clinical Immunology, Department of Medicine IV, 
      Ludwig Maximilians University of Munich, Munich, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - RMD Open
JT  - RMD open
JID - 101662038
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - COVID-19/*prevention & control
MH  - COVID-19 Vaccines/administration & dosage/*adverse effects/therapeutic use
MH  - Humans
MH  - Patient Safety
MH  - *Rheumatic Diseases
MH  - Risk Factors
MH  - SARS-CoV-2
MH  - Vaccination/adverse effects/standards
PMC - PMC7907835
OTO - NOTNLM
OT  - COVID-19
OT  - inflammation
OT  - vaccination
COIS- Competing interests: None declared.
EDAT- 2021/02/26 06:00
MHDA- 2021/03/05 06:00
PMCR- 2021/02/26
CRDT- 2021/02/25 05:35
PHST- 2020/12/20 00:00 [received]
PHST- 2021/01/20 00:00 [revised]
PHST- 2021/02/03 00:00 [accepted]
PHST- 2021/02/25 05:35 [entrez]
PHST- 2021/02/26 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
PHST- 2021/02/26 00:00 [pmc-release]
AID - rmdopen-2020-001553 [pii]
AID - 10.1136/rmdopen-2020-001553 [doi]
PST - ppublish
SO  - RMD Open. 2021 Feb;7(1):e001553. doi: 10.1136/rmdopen-2020-001553.